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 • NEURORADIOLOGY
Cholinergic deficits are a hallmark of Alzheimer disease (AD). The link between cholinergic deficits and cogni-
tive impairment is well established (1) and cholinesterase 
inhibitors (ChEIs) are the mainstay symptomatic pharma-
cotherapy, with moderate effectiveness in established AD 
(2). However, only 18%–48% patients undergoing treat-
ment show clinically significant improvement, and about 
7% of patients develop adverse effects severe enough to 
stop the treatment (3). Additionally, no clinical effect has 
been established in patients with mild cognitive impair-
ment (MCI) (4).
Individual diagnosis of central cholinergic deficits could 
be beneficial to address the lack of treatment response in 
MCI and the variable treatment response in established 
AD. Conceivably, increasing the cholinergic tone in 
patients without a cholinergic deficit is unlikely to lead to 
cognitive improvement, and conversely may make patients 
particularly prone to adverse effects (5). Several markers of 
cholinergic deficits were previously proposed (6–9). How-
ever, none of these markers gained widespread use because 
they are too expensive or invasive, lack robustness, or are 
not widely available. It would be advantageous to identify 
a simple and fast MRI test to reliably map cholinergic defi-
cits as part of the routine MRI work-up (10). Additionally, 
it has been suggested that high-dose ChEI may be more 
efficacious for AD (11), increasing the need for a robust 
cholinergic biomarker to assist selection of candidates for 
potentially more aggressive ChEI treatment.
The nucleus basalis of Meynert (NBM) provides the 
primary source of cholinergic inputs to the cerebral cortex 
and its widespread projections form the NBM cholinergic 
network (12). Resting-state functional connectivity (FC) 
mapping of NBM cholinergic network (hereafter, NBM 
FC) has been demonstrated in healthy people (13), sug-
gesting that it is possible to use NBM FC to delineate cho-
linergic deficits in AD and MCI. NBM FC has a number 
of key advantages for potential clinical use because of its 
noninvasive nature and expected high specificity to map 
cholinergic pathways, given that over 90% of NBM neu-
rons are cholinergic (12). Taken together, NBM FC may 
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Purpose: To determine whether functional connectivity (FC) mapping of nucleus basalis of Meynert (NBM) cholinergic network 
(hereafter, NBM FC) could provide a biomarker of central cholinergic deficits with predictive potential for response to cholinester-
ase inhibitor (ChEI) treatment.
Materials and Methods: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was approved by the institutional review boards 
of all participating sites. All participants and their representatives gave written informed consent prior to data collection. NBM FC 
was examined in 33 healthy control participants, 102 patients with mild cognitive impairment (MCI), and 33 patients with AD 
by using resting-state functional MRI data from the ADNI database. NBM FC was compared between groups before and after 6 
months of ChEI treatment in MCI. Associations between baseline NBM FC and baseline cognitive performance as well as cogni-
tive outcomes after treatment were investigated.
Results: Compared with the healthy control group, NBM FC was decreased in patients with untreated MCI and increased in  
patients with AD treated with ChEI (corrected P , .05). Global cognition (Alzheimer’s Disease Assessment Scale-Cognitive sub-
scale score) was associated with NBM FC (r = 20.349; P , .001). NBM FC was higher 6 months after ChEI compared with 
before ChEI in treated MCI (corrected P , .05), but did not change at 6 months in patients with untreated MCI (corrected P , 
.05). Baseline NBM FC in MCI strongly predicted cognitive outcomes 6 months after ChEI (R2 = 0.458; P = .001).
Conclusion: Functional dissociation of the nucleus basalis of Meynert from a cortical network may explain the cognitive deficits 
in dementia and allow for the selection of individuals who are more likely to respond to cholinesterase inhibitors at early disease 
stages.
© RSNA, 2018
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(14). All participants completed a series of cognitive assessments 
and we chose ADAS-Cog to reflect cognitive function. ADAS-
Cog comprises a comprehensive assessment of cognitive functions 
including memory and executive function that are linked with 
cholinergic function (15) and is commonly used as a primary out-
come neuropsychological measure for AD clinical trials.
Information of dosing schedules for ChEI, memantine, 
and medications with potential anticholinergic effect was 
manually extracted (details in Appendix E1 [online]). At 
the screening visit, five patients with early MCI (8.5%), 
three patients with late MCI (6.3%), and all patients with 
AD were already taking ChEI. Five healthy control partici-
pants (14.7%), nine patients with early MCI (15.2%), four 
patients with late MCI (8.3%), and five patients with AD 
(14.7%) were taking anticholinergic drugs. One patient with 
late MCI (2.1%) and two patients with AD (5.9%) were 
taking memantine at the screening visit. Eight patients with 
early MCI (13.6%) and 13 patients with late MCI (30.2%) 
were prescribed ChEI after the screening visit.
To explore interactions between NBM FC and geno-
type or amyloid pathology as potential confounding factors 
(16,17), we manually extracted the status of APOE ´4 geno-
type and presence of CSF amyloid-b 42 from http://www.
ADNI.org. Participants were designated as APOE ´4 carriers 
if they had one or two copies of allele 4, and as noncarriers 
if they had no allele 4 in their genotype. CSF amyloid-b 
42, rather than amyloid PET, was chosen to reflect abnor-
mal amyloid accumulation, given that it has been recently 
shown that CSF amyloid-b 42 becomes abnormal in the 
earliest stages of AD before amyloid PET starts (18). The 
cutoffs for abnormal CSF amyloid-b 42 used in this study 
were as follows: normal CSF amyloid-b 42 (participants 
with negative CSF Ab 42 status) greater than 201.6 ng/L, 
and abnormal amyloid-b 42 (participants with positive CSF 
Ab 42 status) less than 182.4 ng/L (18). Thirteen partici-
pants did not have APOE data.
Resting-State Functional MRI Acquisition and Quality 
Assessment Protocol
All participants were imaged with a 3.0-T Philips MR unit 
at multiple sites with the same ADNI 3.0-T imaging proto-
col. Participants were instructed to keep their eyes open dur-
ing imaging. The data had been acquired by using a standard 
echo-planar imaging functional MRI protocol (repetition 
time msec/echo time msec, 3000/30; flip angle, 80°; number 
of sections, 48; section thickness, 3.3 mm; 140 volumes; spa-
tial resolution, 3 3 3 3 3 mm3; matrix, 64 3 64).
To account for possible artifacts resulting from micromotion, 
a rigorous protocol of data quality assessment was applied, modi-
fied from a multicenter functional MRI protocol (19), resulting 
in a final data set of 168 participants (33 healthy control partici-
pants, 59 patients with early MCI, 43 patients with late MCI, 
and 33 patients with AD). Good-quality functional MRI images 
6 months after ChEI initiation were available in 12 patients with 
late MCI and in six patients with early MCI. Table 1 summarizes 
demographic, clinical, APOE ´ 4 status, Ab-42 status, and cogni-
tive information of the included participants.
Abbreviations
AD = Alzheimer disease, ADAS-Cog = Alzheimer’s Disease Assessment 
Scale-Cognitive subscale, ADNI = Alzheimer’s Disease Neuroimaging 
Initiative, ChEI = cholinesterase inhibitor, CSF = cerebrospinal fluid, 
FC = functional connectivity, MCI = mild cognitive impairment, NBM 
= nucleus basalis of Meynert
Summary
Nucleus basalis of Meynert functional connectivity metrics obtained 
from resting-state functional MRI have promising prognostic and 
predictive biomarker properties for central cholinergic dysfunction.
Implications for Patient Care
 n The findings suggest that nucleus basalis of Meynert functional 
connectivity metrics obtained from resting-state functional MRI 
have promising biomarker properties for measuring central cholin-
ergic dysfunction and predicting treatment response to cholines-
terase inhibition. 
 n If confirmed in future studies, then nucleus basalis of Meynert 
functional connectivity may assist treatment stratification and 
facilitate ongoing drug development for optimized restoration of 
cholinergic functions in people living with or at risk for dementia.
probe the central cholinergic dysfunction and underlying neuro-
nal degeneration so that we may be able to identify those people 
most likely to benefit from treatment with ChEI.
We hypothesized that reductions of NBM FC are a feature 
of MCI and AD; underlie cognitive impairment across the cog-
nitively normal, MCI, and dementia spectrum not treated with 
ChEI; can be partially reversed with ChEI; and predict treat-
ment response to ChEI in MCI and AD. We then undertook 
a series of posthoc tests to address the role of concurrent use 
of anticholinergic drugs, presence of cerebrospinal fluid (CSF) 
biomarkers of amyloid pathology, apolipoprotein E (APOE) ´4 
genotype, and disease progression.
Materials and Methods
Participants
Data used in the preparation of this article were obtained from 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) da-
tabase (available at https://adni.loni.usc.edu). The ADNI was 
launched in 2003 as a public-private partnership, led by Princi-
pal Investigator Michael W. Weiner, MD. The primary goal of 
ADNI has been to test whether serial MRI, PET, other biologic 
markers, and clinical and neuropsychological assessment can 
be combined to measure the progression of MCI and early AD. 
Written informed consent was obtained from all individuals.
Data were selected based on the availability of resting-state 
functional MRI data and Alzheimer’s Disease Assessment 
Scale-Cognitive subscale (ADAS-Cog) at both screening and 
6 months after initiation of ChEI. As described in the ADNI visit 
schedule, the maximum interval between baseline and screening 
visits was prescribed as 28 days. A total of 175 participants (34 
healthy control participants, 59 patients with early MCI, 48 pa-
tients with late MCI, and 34 patients with AD) were included in 
this study (details of diagnostic criteria in Appendix E1 [online]). 
Demographic and clinical information was used to screen for ex-
isting pathologies, dementia diagnosis, and medication history 
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consecutive functional volumes (21), were treated as further 
between-participant covariates of no interest in all higher-level 
analyses and was carried out by using FMRIB’s Local Analysis 
of Mixed Effects (FLAME) (20) in FSL. Additional outlier de-
weighting in FEAT was used to automatically detect and ac-
count for outlier data points for each voxel.
Posthoc Shapiro-Wilk tests in SPSS were undertaken on 
Z scores extracted from results of the main tests for the four 
hypotheses (described next) to test for normality.
To test hypothesis 1—that NBM FC is lower in patients with 
MCI and patients with AD compared with healthy control par-
ticipants with normal cognitive function—we undertook a voxel- 
based F test to compare the NBM FC maps between groups 
(healthy control participants, patients with MCI, and patients 
with AD) by using multiple test correction within FEAT in FSL. 
Posthoc pairwise t tests (healthy control participants vs patients 
with MCI and healthy control participants vs patients with AD) 
were then used to determine the direction of the effect if the F test 
was significant. Significant level of the t tests was at corrected P , 
.025. Posthoc tests were performed in cohorts not taking anticho-
linergic drugs, and to explore the effects of APOE and Ab status.
To investigate hypothesis 2—that NBM FC correlates with 
cognitive performance but in the absence of an a priori hypoth-
esis of the specific regions affected within the NBM network—
we undertook voxel-based correlation analysis of NBM FC maps 
with ADAS-Cog in the study population not taking ChEI. 
Posthoc tests included correlation analysis in the subgroup of 
participants not taking anticholinergic drugs to prevent possible 
medication-induced confounding effects.
Seed-based FC Analysis
Seed-based FC analysis, which identifies the pattern of brain ar-
eas displaying correlated time series with respect to a predefined 
region, was carried out with software (FMRI Expert Analysis Tool 
[FEAT], version 6.0) in FSL (version 5.0.10; https://fsl.fmrib.ox.ac.
uk/fsl/fslwiki/FEAT) (20) by manually creating a mask (16 voxels, 
581 mm3) in the NBM on functional MRI data sets for each par-
ticipant. The approach of seed-based analysis and the method of 
testing the robustness of manual seed region selection are provided 
in Appendix E2 (online). Standard statistical Z transformation was 
applied to the correlation coefficient of the time series between 
NBM and the rest of the brain in FSL (15); thus, a normal distrib-
uted score was computed to index NBM FC.
Statistical Analysis
One-way analysis of variance and x2 test in SPSS (version 21; 
SPSS, Chicago, Ill) were used to compare demographics and 
cognitive performance between healthy control participants, 
patients with early MCI, patients with late MCI, and patients 
with AD. Statistical significance was set at P , .05.
All main statistical tests and secondary posthoc tests were 
voxel based and corrected for multiple tests as implemented in 
FSL. Inference on first-level analysis was based on Z statistical 
images of each individual thresholded at Z greater than 2.3 and 
a corrected cluster significance threshold of P , .05. Z statistical 
images of voxel-based high-level analyses were estimated based 
on Z greater than 1.96, and a familywise error–corrected cluster 
significance threshold of P , .05. Age and mean relative 
displacement, which is the net amount of motion between 
Table 1: Demographics and Clinical and Cognitive Information
A: Baseline
Parameter HC (n = 33) Early MCI (n = 59) Late MCI (n = 43) AD (n = 33) P Value
 Age (y) 77.1 6 7.3 72.4 6 6.9 73.8 6 8.6 72.8 6 7.2 .03
 Female sex* 18 (54.5) 37 (62.7) 16 (37.2) 16 (48.5) .08
 ADAS-Cog 6.4 6 3.3 8.2 6 3.5 11.4 6 5.4 23.3 6 7.6 ,.001†
 No. of participants undergoing ChEI  
  treatment at baseline*
0 (0) 5 (8.5) 3 (7.0) 33 (100) …
 No. of participants taking anticholinergic  
  medication at baseline*
5 (15.1) 9 (15.2) 4 (9.3) 5 (15.2) .82
 Apolipoprotein ´4 carriers* 9 (29.0) 27 (50.9) 16 (40.0) 24 (77.4) .001†
 Positive CSF amyloid-b 42* 6 (24.0) 18 (36.7) 12 (35.3) 15 (53.6) .16
B: 6 Months after ChEI Treatment
Parameter HC EMCI (n = 8)‡ LMCI (n = 13)‡ AD P Value
 Age (y) … 73.4 6 5.3 72.9 6 8.6 … .90
 Female sex* … 4 (50) 5 (38.5) … .60
 ADAS-Cog … 10.3 6 6.4 13.7 6 5.4 … .21
 ADAS-Cog changes from baseline … 0.9 6 2.7 2.4 6 4.9 … .44
Note.—Unless otherwise specified, data are means 6 standard deviations. AD = Alzheimer disease, ADAS-Cog = Alzheimer’s Disease As-
sessment Scale-Cognitive subscale, ChEI = cholinesterase inhibitor, CSF = cerebrospinal fluid, HC = healthy control participants, MCI = 
mild cognitive impairment.
* Data are numbers, with percentages in parentheses.
† Significant level at P , .05.
‡ In total, eight patients with early MCI and 13 patients with late MCI had ADAS-Cog score 6 months after undergoing ChEI treatment. 
Among these patients, six patients with early MCI and 12 patients with late MCI patients had good-quality resting-state functional MR 
images at 6 months after undergoing ChEI treatment.
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Results
A total of 168 participants (mean age 
6 standard deviation, 73.8 years 6 
7.7; 87 women [51.8%] and 81 men 
[49.2]) were included. Figure 1 shows 
the flowchart of the participant se-
lection. Healthy control participants 
were significantly older than were 
patients with MCI and patients with 
AD (P = .03) (Table 1). The manual 
method to define NBM FC maps 
was considered robust (Appendix E2 
[online]).
NBM FC Pattern in Healthy 
Aging and Abnormalities in 
MCI and AD
In healthy control participants, 
the NBM was functionally con-
nected with the anterior cingulate 
cortex, bilateral hippocampi, cau-
date, medial frontal gyri, insular 
cortex, superior temporal gyri, and 
occipital lobes (Fig 2, A). Patients 
with MCI (Fig 2, B) and patients 
with AD (Fig 2, C) showed quali-
tatively similar NBM FC patterns 
but additional NBM FC was seen 
in AD with the bilateral occipi-
tal lobes, bilateral medial tempo-
ral gyri, and posterior cingulate 
cortex. F test showed a significant 
between-group difference of NBM 
FC between healthy control partici-
pants, patients with MCI, and pa-
tients with AD (Fig E1 [online]). By using further pairwise 
t tests, we found that patients with MCI at baseline had 
decreased NBM FC in the anterior cingulate cortex, bilat-
eral hippocampus, bilateral caudate, bilateral insular cortex, 
bilateral superior and medial temporal gyri, and bilateral 
occipital lobes, compared with healthy control participants 
(Fig 2, D; Table 2). Also, group comparison confirmed sig-
nificantly increased NBM FC with the right hippocampus, 
left middle and inferior frontal gyri, and bilateral superior 
temporal gyrus in patients with AD compared with healthy 
control participants (Fig 2, F; Table 2) when age and mean 
relative displacement were controlled.
Effects of Age, Anticholinergic Drugs, Disease 
Progression, Genotype, and Amyloid Pathology on 
NBM FC
We ran several posthoc analyses to explore possible moderator 
factors. In healthy control participants and patients with MCI 
without ChEI or anticholinergic drugs, there was no signifi-
cant correlation between age and Z score of clusters showing 
increased NBM FC in AD compared with healthy control par-
ticipants (P = .74).
To study hypothesis 3—that ChEI would increase NBM 
FC without an a priori hypothesis of where these effects 
would be—we again used voxel-based change analysis of 
NBM FC maps comparing before ChEI treatment and 
6 months after ChEI initiation in 18 patients with MCI 
(voxel-based paired t test FEAT in FSL corrected for mul-
tiple comparisons). In view of the naturalistic study design, 
we sought to control for possible disease progression effects 
that might confound our change analysis. Hence, we as-
sessed possible serial disease progression effects of NBM FC 
maps over an interval of 6 months in a matched (for age, 
sex, and disease severity) group of 18 patients with MCI 
(six with early MCI and 12 with late MCI) who did not un-
dergo ChEI treatment in the interval by using voxel-based 
paired t test in FEAT as posthoc test.
Last, we studied the hypothesis that low NBM FC would 
predict the cognitive response to ChEI. We used voxel-wise 
correlation analysis of baseline NBM FC maps with changes 
of ADAS-Cog 6 months after initiating ChEI. Again, because 
of the naturalistic study design, we assessed whether NBM 
FC at baseline might also predict cognitive change in an un-
treated cohort (posthoc test).
Figure 1: Flowchart shows participant selection. AC = anticholinergic treatment, AD = Alzheimer 
disease, ADAS-Cog = Alzheimer’s Disease Assessment Scale-Cognitive subscale, ADNI = Alzheimer’s 
Disease Neuroimaging Initiative, ChEI = cholinesterase inhibitor, EMCI = early mild cognitive 
impairment, HC = healthy control participants, LMCI = late mild cognitive impairment, MCI = mild 
cognitive impairment.
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NBM FC and Cognitive Impairment
A significant but modest negative correlation (r = 20.349; P 
, .001) (Fig 3, Table 2) was found between baseline ADAS-
Cog and NBM FC with the posterior cingulate cortex, an-
terior cingulate cortex, bilateral caudate, bilateral putamen, 
bilateral thalamus, left insular cortex, left hippocampus, left 
middle frontal gyrus, and right middle temporal gyrus in the 
group of participants not taking ChEI at baseline (n = 127 [33 
healthy control participants and 54 patients with MCI]). This 
correlation was largely unchanged when 16 participants who 
were taking anticholinergic drugs were excluded (n = 111; r = 
20.351; P , .001) (Fig E3 [online]).
To control for a possible general cognitive effect exerted by 
loss of global FC, and specifically impaired FC in the posterior 
cingulate cortex, we investigated whether posterior cingulate 
cortex or primary visual cortex FC was associated with ADAS-
Cog. No significant correlation between cognitive performance 
and posterior cingulate cortex or primary visual cortex FC was 
identified, supporting a weak but specific association between 
NBM FC and cognition.
We repeated the between-group comparison after exclusion 
of participants who were taking anticholinergic drugs, which 
revealed similar results as in the whole cohort (Fig E2 [online]).
To further explore the effects of disease progression without 
confounding effects from ChEI or anticholinergic drugs, we also 
compared patients with untreated early MCI and untreated late 
MCI. The results revealed a decreased NBM FC with the right 
parietal lobe, right postcentral gyrus, right lateral occipital cor-
tex, right insula, and precuneus in late MCI compared with early 
MCI (age and mean relative displacement–controlled, family-
wise error–corrected P , .05) (Fig 2, E; Table 2).
To explore the effect of genotype and amyloid pathology 
on NBM FC without confounding effects from ChEI or an-
ticholinergic drugs, binary logistic regression analyses between 
the status of APOE ´4, amyloid-b 42 status, and Z scores of 
clusters showing difference of NBM FC (healthy control par-
ticipants vs patients with AD) were conducted. No significant 
correlation was found between the Z score of clusters show-
ing increased NBM FC in AD and the status of APOE ´4 
(P = .26) or amyloid-b 42 status (P = .27).
Figure 2: Images show functional connectivity (FC) mapping of nucleus basalis of Meynert (NBM) cholinergic network (hereafter, NBM FC) 
(whole cohort) in, A, healthy aging (healthy control participants [HC], n = 33; corrected P , .05) and also shows seed mask (green), B, in pa-
tients with mild cognitive impairment (MCI) (n = 102; corrected P , .05), and, C, in patients with Alzheimer disease (AD) (n = 33; corrected P 
, .05). Significance was set at P , .05. D, Difference NBM FC map between MCI and HC (blue-light blue indicates reductions in MCI; pairwise 
t test, corrected P , .025). E, Difference NBM FC between late MCI (LMCI) and early MCI (EMCI) (blue-light blue indicates reductions in LMCI; 
posthoc pairwise t test, P , .05). F, Difference NBM FC between AD and HC (red-yellow indicates increased FC in AD; pairwise t test, corrected 
P , .025). All results were masked by gray matter masks obtained from Montreal Neurological Institute 152 standard-space T1-weighted average 
structural template image. All t test analyses were controlled for age and mean relative displacement. 
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Table 2: Brain Regions Where NBM FC Are Associated with Cognition and Cholinesterase Inhibitory Effects
Coordinates (mm)
Parameter X Y Z Z Value*
Decreased NBM FC in patients with MCI compared with HC
 Left caudate 216 22 2 2.49
 Right caudate 14 24 2 2.62
 Left insular cortex 238 212 4 2.56
 Right insular cortex 40 4 6 3.38
 Right superior temporal gyrus 60 26 4 2.42
 Left middle temporal gyrus 256 238 22 2.90
 Right middle temporal gyrus 54 234 22 3.35
Increased NBM FC in patients with AD compared with HC
 Right hippocampus 32 220 210 2.42
 Left middle frontal gyrus 242 56 0 2.89
 Left inferior frontal gyrus 250 24 4 3.03
 Left middle occipital gyrus 234 290 4 2.45
 Right superior temporal gyrus 54 234 8 2.49
 Right inferior parietal lobule 64 240 24 3.12
 Left inferior parietal lobule 248 238 24 2.89
Decreased NBM FC in late MCI compared with early MCI
 Right parietal lobe 42 224 18 3.38
 Right postcentral gyrus 54 224 36 2.95
 Right lateral occipital cortex 46 268 38 2.11
 Right insula 44 228 14 3.06
 Precuneus 22 260 22 2.41
Negative correlation between baseline NBM FC and ADAS-Cog
 Posterior cingulate cortex 26 246 30 3.47
 Anterior cingulate cortex 6 18 214 3.62
 Left caudate 212 10 10 2.37
 Right caudate 16 10 10 2.98
 Left putamen 226 24 24 2.89
 Right putamen 20 10 22 2.66
 Left thalamus 26 214 2 2.60
 Right thalamus 6 212 2 2.76
 Left insular cortex 238 20 2 2.42
 Left hippocampus 228 222 214 2.36
 Left middle frontal gyrus 246 14 32 3.70
 Right middle temporal gyrus 50 266 16 3.27
Increased NBM FC at 6 mo after ChEI treatment compared with NBM FC at baseline
 Right putamen 20 10 10 2.89
 Left superior frontal gyrus 216 44 42 2.94
 Right middle frontal gyrus 30 4 44 2.32
 Anterior cingulate cortex 26 8 46 2.38
Positive correlation between baseline NBM FC and ADAS-Cog changes
 Left lateral occipital cortex 228 274 44 2.63
 Left medial frontal gyrus 22 34 32 2.54
Negative correlation between baseline NBM FC and ADAS-Cog changes
 Anterior cingulate cortex 24 26 16 3.37
Note.—AD = Alzheimer disease, ADAS-Cog = Alzheimer’s Disease Assessment Scale-Cognitive subscale, ChEI = cholinesterase inhibitor, 
HC = healthy control participants, FC = functional connectivity, MCI = mild cognitive impairment, NBM = nucleus basalis of Meynert.
* All statistical images were thresholded at a familywise error–corrected threshold of P , .05.
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line NBM FC in 18 patients with untreated MCI (mean 
age, 72.8 years 6 5.1; seven women [38.9%] and 11 men 
[61%]; six with early MCI and 12 with late MCI) with their 
6-month follow-up NBM FC, which did not reveal significant 
changes.
NBM FC at Baseline to Predict Cognitive Outcome 
after ChEI
We then assessed the potential of baseline NBM FC to predict 
the cognitive outcome after 6 months of ChEI. NBM FC in 
both the lateral cholinergic network (left lateral occipital cor-
tex) and the medial cholinergic network (left medial frontal 
gyrus) was strongly and positively correlated with changes in 
NBM FC Changes after Initiation of ChEI
A total of 18 patients with MCI (mean age, 72.2 years 6 
7.3; seven women [38.9%] and 11 men [61%]; six with early 
MCI and twelve with late MCI) underwent functional MRI 
before and 6 months after starting ChEI. Compared with 
pretreatment, the 6-month follow-up images showed signifi-
cantly increased FC between NBM and the right putamen, 
right caudate, left superior frontal gyrus, right middle fron-
tal gyrus, and anterior cingulate cortex (corrected P = .001) 
(Fig 4, Table 2). Because of the naturalistic ADNI cohort 
design, the observed serial changes may be related to disease 
progression rather than to ChEI treatment. To control for 
such potentially confounding effects, we compared the base-
Figure 3:  Images show functional connectivity (FC) mapping of nucleus basalis of Meynert (NBM) cholinergic network (hereafter, NBM FC) 
and cognition. Negative correlation map between baseline Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and NBM FC 
located in significant clusters (blue-light blue) in group of participants including healthy control participants (HC), patients with early mild cognitive 
impairment (EMCI), and patients with late mild cognitive impairment (LMCI) who were not undergoing cholinesterase inhibitor (ChEI) treatment (n 
= 127). All results were masked by gray matter masks obtained from Montreal Neurological Institute 152 standard-space T1-weighted average 
structural template image. Scatterplot shows negative correlation between baseline ADAS-Cog and FC between NBM and significant clusters. All 
analyses were controlled for age and mean relative displacement. Significance was set at corrected P , .05. MCI = mild cognitive impairment.
Figure 4: Images show serial changes in functional connectivity (FC) mapping of nucleus basalis of Meynert (NBM) cholinergic network (hereaf-
ter, NBM FC) between baseline and 6 months after undergoing cholinesterase inhibitor (ChEI) treatment in 18 patients with mild cognitive impair-
ment (MCI). NBM FC significantly increased from baseline to 6 months after ChEI in right anterior striatum and prefrontal cortex (red-yellow). Box 
plot shows distribution of strength of FC between NBM and significant clusters (red-yellow) before and 6 months after ChEI, indexed as Z score. All 
results were masked by gray matter masks obtained from Montreal Neurological Institute 152 standard-space T1-weighted average structural tem-
plate image. Significance level was at familywise error–corrected P , .05 (corrected for multiple comparisons) and corrected for age and mean 
displacement.
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by using the publicly available ADNI data sets. Seeding FC 
maps in the NBM allowed us to identify established cortical 
and subcortical networks with known cholinergic innerva-
tion by the NBM. Four main findings demonstrated diag-
nostic, prognostic, and predictive biomarker properties. First, 
NBM FC was decreased in patients with untreated MCI, 
but was increased in patients with early AD who were taking 
ChEI compared with the control group. Second, global cog-
nitive performance in healthy participants and patients with 
untreated MCI was correlated with NBM FC predominantly 
in the default mode network. Third, the NBM FC deficit was 
partially responsive to indirect cholinomimetic treatment in 
patients with MCI, showing significant increases 6 months 
after ChEI initiation, but not in an untreated parallel group. 
Fourth, baseline NBM FC strongly predicted cognitive out-
comes in patients with MCI 6 months after starting ChEI, 
but not in an untreated parallel group.
The pattern of cortical and subcortical NBM FC, includ-
ing hubs of the default mode and the salience networks and the 
bilateral caudate nuclei, is largely consistent with the anatomic 
identification of the medial and lateral cholinergic pathways (22) 
and a previous report in healthy younger people (13). Specifi-
cally, the medial cholinergic pathway matches the FC between 
ADAS-Cog scores over 6 months of ChEI (R2, 0.458; P = .001) 
(Fig 5, A; Table 2) in line with the hypothesis that lower FC 
may predict increased benefits from ChEI. Unexpectedly, we 
also found a similarly strong anticorrelation between NBM FC 
in the medial cholinergic network (anterior cingulate cortex) 
and ADAS-Cog changes 6 months after starting ChEI (R2 
= 0.366; P = .006) (Fig 5, B; Table 2). To further control 
for possible confounding predictor effects associated with dis-
ease progression but unrelated to ChEI, we studied the associa-
tion between NBM FC at baseline and ADAS-Cog changes 6 
months after baseline in 21 patients with MCI who did not 
take ChEI in the interval, which did not reveal significant as-
sociations. Additionally, to investigate whether APOE ´4 or 
amyloid-b 42 status had an effect on the predictive power of 
NBM FC on treatment response, the association between the 
Z score of clustering showing positive correlation with ADAS-
Cog changes (Fig 5, A) and APOE ´4 and amyloid-b 42 status 
was explored, but no significant results were revealed (APOE 
´4, P = .94; amyloid-b 42 status, P = .25).
Discussion
Our study investigated the potential of basal forebrain FC as 
a biomarker of cholinergic dysfunction in MCI and early AD 
Figure 5: Images show correlation between baseline functional connectivity (FC) mapping of nucleus basalis of Meynert (NBM) cholinergic net-
work (hereafter, NBM FC) and changes of cognitive performance assessed by Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-
Cog) over 6 months of treatment with cholinesterase inhibitor. A, Positive correlation between ADAS-Cog change (posttreatment minus pretreat-
ment; positive difference represents worsening cognition) and baseline NBM FC (red) in patients with mild cognitive impairment (MCI). Scatterplot 
illustrates positive correlation for significant clusters. B, Negative correlation between changes of ADAS-Cog and NBM FC (blue) at baseline in 
patients with MCI. Scatterplot shows negative correlation in significant clusters. Dotted lines in scatterplots indicate three-point change (improve/
decline) on ADAS-Cog, which is considered as clinically relevant. All analyses were controlled for age and mean relative displacement. All results 
were masked by gray matter masks obtained from Montreal Neurological Institute 152 standard-space T1-weighted average structural template im-
age. Significance level was at corrected P , .05.
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enhanced brain activity as shown in pharmacologic functional 
MRI studies (33). Taken together, our results of increased FC 
between NBM and left superior frontal gyrus and right middle 
frontal gyrus at rest after ChEI treatment may explain increased 
task responsiveness shown previously (33). However, in our 
study, we cannot directly allocate the observed NBM FC change 
to a pharmacologic effect of ChEI because of the naturalistic 
design. Nevertheless, in a matched cohort of patients with un-
treated MCI, we did not find a serial effect of NBM FC over 
6 months supporting our interpretation that the observed NBM 
FC changes after ChEI reflect cholinomimetic effects rather than 
the disease process.
It would be clinically useful to identify patients who will 
benefit most from ChEI to improve the treatment effective-
ness in established AD, and to enable stratification of patients 
with MCI for future treatment trials. Although clinical ef-
fectiveness of ChEI has not been proven in patients with 
MCI, it is conceivable that only those patients with MCI 
with reduced NBM FC may benefit more from ChEI. We 
observed a pattern of reduced NBM FC at baseline that was 
associated with better cognitive outcomes at 6 months after 
taking ChEI, mainly located in the left lateral occipital cor-
tex (lateral cholinergic pathway) and the left middle frontal 
gyrus (medial cholinergic pathway), supporting the notion 
that imaging metrics have the potential to predict the cog-
nitive response to ChEI in MCI and AD (34,35). By con-
trast, baseline NBM FC was not associated with cognitive 
outcome in those patients with MCI who did not take ChEI 
in the 6-month interval, making a confounding predic-
tive effect of cognitive decline from disease progression less 
likely. The predictive potential is large as the overall effect 
was strong, with several clusters explaining up to 48% of the 
variance in cognitive outcome. Interestingly, we also observed 
a pattern of negative correlation between baseline NBM FC, 
mainly located in the anterior cingulate cortex, and cogni-
tive change 6 months after taking ChEI. The direction of this 
association may be explained by the known high degree of 
regional heterogeneity of cholinergic receptors and possible 
disease stage effects (36).
Clinical translational potential of NBM FC is particularly 
high because task-free resting-state functional MRI can be eas-
ily incorporated into the current routine diagnostic work-up of 
patients with memory complaints. If the prediction of treatment 
response can be confirmed in prospective studies, then NBM FC 
could broaden the clinical remit of MRI for work-up of mem-
ory impairment beyond the current diagnostic support to assist 
treatment stratification.
Our study was limited by the design of the ADNI study. 
All the participants with AD had already started to take ChEI 
when they were recruited. Thus, we could not investigate the 
effects of ChEI on NBM FC in patients with AD. Because 
of the observational nature of the ADNI study, our findings 
on ChEI effects on NBM FC and the prediction of cogni-
tive outcomes by NBM FC could not be placebo controlled. 
However, serial data were available in matched patients with 
untreated MCI, allowing us to make a serial effect from 
disease progression unlikely. Because of the small cohort of 
NBM and medial prefrontal cortices, anterior cingulate cortex, 
and subcortical regions. The capsular division of the lateral cho-
linergic pathway is consistent with the FC between NBM and 
bilateral hippocampi, as is the perisylvian division with the FC 
between NBM and bilateral insula. Different from Li et al (13), 
we did not find areas that were anticorrelated with NBM, which 
can be explained by the fact that we avoided to regress out global 
signal changes, thereby minimizing spurious negative cross-cor-
relations between brain regions (23).
Compared with healthy control participants, patients with 
MCI showed decreased NBM FC within both the medial and 
lateral cholinergic system. This finding is well in line with the 
early neurodegeneration of the NBM and several PET stud-
ies showing a widespread reduction of acetylcholine activi-
ties in MCI (25,26). The results are also in broad accordance 
with two recent NBM FC studies in MCI (27) and MCI in 
Parkinson disease (28) showing reduced NBM FC associated 
with cognitive deficits. However, we found a more extended 
pattern of NBM FC deficit in MCI compared with Li et al 
(27), which may be related to our postprocessing method and 
the medication effects. Further decrease of NBM FC in cases 
of late MCI versus early MCI supports the progressive nature 
of cholinergic dysfunction.
In a large group of healthy control participants and patients 
with MCI who were not taking ChEI, we showed a significant 
but modest correlation between cognitive performance and 
NBM FC within the medial and lateral cholinergic system. 
Findings were not affected by excluding participants who were 
taking anticholinergic drugs. The regions within the NBM 
FC network showing associations with cognitive performance 
partly overlap with the default mode network such as the pos-
terior cingulate cortex and the frontal, temporal, and parietal 
cortices. The pattern identified and the direction of associa-
tion provide further support for the cholinergic hypothesis of 
dementia (2) in line with previous studies showing reduced 
acetylcholine activities in multiple brain regions by using PET 
imaging techniques (29,30).
Interestingly, we did not find a further decrease of NBM FC 
in AD, but we observed an increased NBM FC in patients with 
AD compared with healthy control participants. This finding—
at first surprising—may be related to a treatment effect, as the 
ADNI repository only holds data from patients with AD already 
receiving treatment with ChEI. In line with pharmacologic im-
aging studies showing increased activation after cholinergic chal-
lenge (31,32), ChEI is expected to increase the cholinergic tone 
and the NBM FC. However, this interpretation remains specula-
tive without comparison with NBM FC maps of patients with 
untreated AD.
To further characterize a possible treatment effect, we studied 
serial NBM FC changes between baseline and 6-month post-
treatment data in a subgroup of patients with MCI. This showed 
significantly increased NBM FC within the right putamen, right 
caudate, left superior frontal gyrus, and right middle frontal gy-
rus compared with pretreatment, suggesting at least partial resto-
ration of cholinergic modulation of neural activities. This result 
concords well with the expected treatment effects of ChEI to 
restore synaptic activities within the cholinergic pathways and 
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patients undergoing ChEI, for the comparison of NBM FC 
before and after 6 months of ChEI treatment, we chose a 
less rigorous multiple test correction at the voxel level alone. 
Larger, prospective studies are needed to confirm the reported 
treatment changes of NBM FC and the predictive value of 
NBM FC at baseline. Another potential limitation was the 
robustness of the seed-based analysis because of the small 
size and ill-defined borders of the NBM at functional MRI, 
making manual delineation challenging. We addressed this 
by showing the robustness of the manual drawing method 
against small shifts of the seeds by using an in-house Matlab 
(version R2016a; Mathworks, Natick, Mass) code. This step 
could be improved by semiautomatic seed selection.
In summary, our study shows that NBM FC metrics ob-
tained from a brief task-free functional MRI at 3.0 T has 
promising prognostic and predictive biomarker properties for 
central cholinergic dysfunction. If confirmed in prospective 
studies, then NBM FC could assist treatment stratification and 
facilitate ongoing drug development for optimized restoration 
of cholinergic functions in people living with or at risk for 
dementia.
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